In-depth behavioral characterization of the corticosterone mouse model and the critical involvement of housing conditions

Physiology and Behavior

Volumn 156, Issue , 2016, Pages 199-207

  Demuyser, Thomas ^a   Deneyer, Lauren ^a   Bentea, Eduard ^a   Albertini, Giulia ^a   Van Liefferinge, Joeri ^a   Merckx, Ellen ^a   De Prins, An ^a   De Bundel, Dimitri ^a   Massie, Ann ^a   Smolders, Ilse ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Anxiety; Corticosterone; Depression; Face validity; Housing; Mouse model

Indexed keywords

CORTICOSTERONE; CORTICOSTERONE 21 ACETATE; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; ELEVATED T-MAZE TEST; EXPLORATORY BEHAVIOR; FACE VALIDITY; FORCED SWIM TEST; HOUSING; IMMOBILITY; LOCOMOTION; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; PHYSIOLOGY; PRIORITY JOURNAL; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; IMMOBILIZATION; MOTOR ACTIVITY;

ANIMALS; BEHAVIOR, ANIMAL; CORTICOSTERONE; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GLUCOCORTICOIDS; HINDLIMB SUSPENSION; HOUSING; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY;

EID: 84955567389     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.12.018     Document Type: Article

References (41)

1. Ferrari A.J., Charlson F.J., Norman R.E., Patten S.B., Freedman G., Murray C.J., et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013, 10.
2. Hirschfeld R.M. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim. Care Companion J. Clin. Psychiatry 2001, 3:244-254.
3. Waters P., McCormick C.M. Caveats of chronic exogenous corticosterone treatments in adolescent rats and effects on anxiety-like and depressive behavior and hypothalamic-pituitary-adrenal (HPA) axis function. Biol. Mood Anxiety Disord. 2011, 1:4.
4. Cryan J.F., Slattery D.A. Animal models of mood disorders: recent developments. Curr. Opin. Psychiatry 2007, 20:1-7.
5. Stetler C., Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 2011, 73:114-126.
6. Hiller-Sturmhofel S., Bartke A. The endocrine system: an overview. Alcohol Health Res. World 1998, 22:153-164.
7. Joels M., Sarabdjitsingh R.A., Karst H. Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol. Rev. 2012, 64:901-938.
8. Snyder J.S., Soumier A., Brewer M., Pickel J., Cameron H.A. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011, 476:458-461.
9. Sapolsky R.M. Atrophy of the hippocampus in posttraumatic stress disorder: how and when?. Hippocampus 2001, 11:90-91.
10. Murray F., Smith D.W., Hutson P.H. Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. Eur. J. Pharmacol. 2008, 583:115-127.
11. Gourley S.L., Kiraly D.D., Howell J.L., Olausson P., Taylor J.R. Acute hippocampal brain-derived neurotrophic factor restores motivational and forced swim performance after corticosterone. Biol. Psychiatry 2008, 64:884-890.
12. David D.J., Samuels B.A., Rainer Q., Wang J.W., Marsteller D., Mendez I., et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009, 62:479-493.
13. Rainer Q., Xia L., Guilloux J.P., Gabriel C., Mocaer E., Hen R., et al. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int. J. Neuropsychopharmacol. 2012, 15:321-335.
14. Mei L., Mochizuki M., Hasegawa N. Pycnogenol ameliorates depression-like behavior in repeated corticosterone-induced depression mice model. BioMed Res. Int. 2014, 2014:942927.
15. van Donkelaar E.L., Vaessen K.R., Pawluski J.L., Sierksma A.S., Blokland A., Canete R., et al. Long-term corticosterone exposure decreases insulin sensitivity and induces depressive-like behaviour in the C57BL/6NCrl mouse. PLoS One 2014, 9.
16. Khalid A., Kim B.S., Chung M.K., Ye J.C., Jeon D. Tracing the evolution of multi-scale functional networks in a mouse model of depression using persistent brain network homology. NeuroImage 2014, 101:351-363.
17. Sturm M., Becker A., Schroeder A., Bilkei-Gorzo A., Zimmer A. Impact of chronic corticosterone application on depression-like behavior in C57BL/6N and C57BL/6J mice. Genes Brain Behav. 2015.
18. Zhao Y., Ma R., Shen J., Su H., Xing D., Du L. A mouse model of depression induced by repeated corticosterone injections. Eur. J. Pharmacol. 2008, 581:113-120.
19. Yoon S.H., Kim B.H., Ye S.K., Kim M.H. Chronic non-social stress affects depressive behaviors but not anxiety in mice. Korean J. Physiol. Pharmacol. 2014, 18:263-268.
20. Rosa P.B., Ribeiro C.M., Bettio L.E., Colla A., Lieberknecht V., Moretti M., et al. Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice. Pharmacol. Biochem. Behav. 2014, 127C:1-6.
21. Ali S.H., Madhana R.M., K V.A., Kasala E.R., Bodduluru L.N., Pitta S., et al. Resveratrol ameliorates depressive-like behavior in repeated corticosterone-induced depression in mice. Steroids 2015, 101:37-42.
22. Ardayfio P., Kim K.S. Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. Behav. Neurosci. 2006, 120:249-256.
23. Zhao Y., Xie W., Dai J., Wang Z., Huang Y. The varying effects of short-term and long-term corticosterone injections on depression-like behavior in mice. Brain Res. 2009, 1261:82-90.
24. Voikar V., Polus A., Vasar E., Rauvala H. Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences. Genes Brain Behav. 2005, 4:240-252.
25. Kwak C., Lee S.H., Kaang B.K. Social isolation selectively increases anxiety in mice without affecting depression-like behavior. Korean J. Physiol. Pharmacol. 2009, 13:357-360.
26. Linge R., Pazos A., Diaz A. Social isolation differentially affects anxiety and depressive-like responses of bulbectomized mice. Behav. Brain Res. 2013, 245:1-6.
27. Liu X., Wu R., Tai F., Ma L., Wei B., Yang X., et al. Effects of group housing on stress induced emotional and neuroendocrine alterations. Brain Res. 2013, 1502:71-80.
28. Kilkenny C., Browne W., Cuthill I.C., Emerson M., Altman D.G. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160:1577-1579.
29. Bentea E., Demuyser T., Van Liefferinge J., Albertini G., Deneyer L., Nys J., et al. Absence of system xc- in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 59:49-58.
30. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
31. Cryan J.F., Lucki I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine(2C) receptors. J. Pharmacol. Exp. Ther. 2000, 295:1120-1126.
32. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
33. Bachmanov A.A., Tordoff M.G., Beauchamp G.K. Sweetener preference of C57BL/6ByJ and 129P3/J mice. Chem. Senses 2001, 26:905-913.
34. Mineur Y.S., Picciotto M.R., Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol. Psychiatry 2007, 61:250-252.
35. Rodgers R.J., Cole J.C., Aboualfa K., Stephenson L.H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol. Biochem. Behav. 1995, 52:805-813.
36. Pogorelov V.M., Lanthorn T.H., Savelieva K.V. Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J. Neurosci. Methods 2007, 162:222-228.
37. Belzung C., Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. Mood Anxiety Disord. 2011, 1:9.
38. Kumar V., Kim K., Joseph C., Kourrich S., Yoo S.H., Huang H.C., et al. C57BL/6N mutation in cytoplasmic FMRP interacting protein 2 regulates cocaine response. Science 2013, 342:1508-1512.
39. Matsuo N., Takao K., Nakanishi K., Yamasaki N., Tanda K., Miyakawa T. Behavioral profiles of three C57BL/6 substrains. Front. Behav. Neurosci. 2010, 4:29.
40. Bryant C.D., Zhang N.N., Sokoloff G., Fanselow M.S., Ennes H.S., Palmer A.A., et al. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J. Neurogenet. 2008, 22:315-331.
41. Fonio E., Benjamini Y., Golani I. Short and long term measures of anxiety exhibit opposite results. PLoS One 2012, 7.